Sonoma Pharmaceuticals (NASDAQ:SNOA) Shares Cross Above 200-Day Moving Average – Time to Sell?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.10 and traded as high as $2.67. Sonoma Pharmaceuticals shares last traded at $2.58, with a volume of 35,479 shares changing hands.

Sonoma Pharmaceuticals Stock Performance

The company has a market cap of $3.51 million, a P/E ratio of -0.53 and a beta of 1.41. The business’s fifty day moving average is $2.74 and its two-hundred day moving average is $2.12.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC acquired a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned 1.08% of Sonoma Pharmaceuticals at the end of the most recent reporting period. 1.95% of the stock is owned by hedge funds and other institutional investors.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.